This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Resources

Real World Experience

with EYLEA® (aflibercept) 8 mg

Eye banner image

Explore real world clinician experience of implementing treatment with EYLEA® (aflibercept) 8 mg in the UK. These resources highlight the potential of EYLEA 8 mg to address unmet needs in the treatment of nAMD and DMO.

UK Audits of EYLEA 8 mg Treatment for Patients with nAMD


Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust

 

In this video, Serena Salvatore presents the drying effects of EYLEA 8 mg from an audit conducted at Bristol Eye Hospital. The video discusses the results of treating 352 naïve patients with EYLEA 8 mg.

  • Duration: 8 minutes
  • Treatment-naïve patients
  • nAMD

Prescribing information for EYLEA® (aflibercept) can be found here.

Early real-world experiences with EYLEA 8 mg booklet

This downloadable booklet presents outcomes from UK case studies conducted at:

  • Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust
  • Newmedica Eye Health Clinic & Surgical Centre, Grimsby
  • Western Eye Hospital, Imperial College Healthcare NHS Trust

nAMD and DMO Patient Case Study Discussion ~30 minutes

Features Richard Gale, Hani Hasan and Rossella Anzidei, each presenting up to two cases of patients with neovascular age related macular degeneration or visual impairment due to diabetic macular oedema treated with EYLEA 8 mg. The management of each case is then discussed by the panel.

Prescribing information for EYLEA® (aflibercept) can be found here.

Please refer to the links below to hear from other experts who have used EYLEA 8 mg, and explore a variety of on-demand resources created in collaboration with both local and internationally recognised leaders in medical retina.

Early Insights Case Study Webinar Series
Key experts in medical retina, from both the UK and the US, discuss their patient cases
Retinal Pioneers Programme
A source of on-demand, educational resources developed in collaboration with national and international thought leaders

Abbreviations

DMO, diabetic macular oedema. nAMD, neovascular (wet) age-related macular degeneration. NHS, National Health Service.

EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2321, September 2024
HCP Resources
Access useful, downloadable ophthalmology resources for HCPs
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg

PP-EYL-GB-2790 | March 2025